VentriPoint Diagnostics Ltd
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers. It also provid… Read more
VentriPoint Diagnostics Ltd (VPTDF) - Net Assets
Latest net assets as of September 2025: $-4.66 Million USD
Based on the latest financial reports, VentriPoint Diagnostics Ltd (VPTDF) has net assets worth $-4.66 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($377.12K) and total liabilities ($5.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.66 Million |
| % of Total Assets | -1235.01% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 635.07 |
VentriPoint Diagnostics Ltd - Net Assets Trend (2005–2024)
This chart illustrates how VentriPoint Diagnostics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VentriPoint Diagnostics Ltd (2005–2024)
The table below shows the annual net assets of VentriPoint Diagnostics Ltd from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-2.98 Million | -1671.84% |
| 2023-12-31 | $189.71K | -95.83% |
| 2022-12-31 | $4.55 Million | -45.36% |
| 2021-12-31 | $8.33 Million | +454.85% |
| 2020-12-31 | $-2.35 Million | +4.89% |
| 2019-12-31 | $-2.47 Million | -153.73% |
| 2018-12-31 | $-973.26K | +40.15% |
| 2017-12-31 | $-1.63 Million | +27.72% |
| 2016-12-31 | $-2.25 Million | -734.34% |
| 2015-12-31 | $-269.66K | +88.74% |
| 2014-12-31 | $-2.40 Million | +23.25% |
| 2013-12-31 | $-3.12 Million | -17.78% |
| 2012-12-31 | $-2.65 Million | -13.81% |
| 2011-12-31 | $-2.33 Million | -170.70% |
| 2010-12-31 | $-860.17K | +73.60% |
| 2009-12-31 | $-3.26 Million | -74.01% |
| 2008-12-31 | $-1.87 Million | -174.75% |
| 2007-12-31 | $2.50 Million | +273.59% |
| 2006-12-31 | $670.44K | -3.58% |
| 2005-12-31 | $695.36K | -- |
Equity Component Analysis
This analysis shows how different components contribute to VentriPoint Diagnostics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5830888331.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $43.78 Million | % |
| Other Comprehensive Income | $45.24K | % |
| Other Components | $11.61 Million | % |
| Total Equity | $-2.98 Million | 100.00% |
VentriPoint Diagnostics Ltd Competitors by Market Cap
The table below lists competitors of VentriPoint Diagnostics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PEPTONIC MEDICAL
F:28L
|
$14.71 Million |
|
Murray Cod Australia Ltd
AU:MCA
|
$14.71 Million |
|
Delta Djakarta Tbk
JK:DLTA
|
$14.71 Million |
|
Sutlej Textiles and Industries Limited
NSE:SUTLEJTEX
|
$14.72 Million |
|
Dreamfolks Services Limited
NSE:DREAMFOLKS
|
$14.70 Million |
|
China Changbaishan International Holdings Limited
F:CL70
|
$14.69 Million |
|
Skane mollan AB
ST:SKMO
|
$14.69 Million |
|
Bokusgruppen AB
ST:BOKUS
|
$14.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VentriPoint Diagnostics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 189,706 to -2,981,871, a change of -3,171,577 (-1671.8%).
- Net loss of 4,919,573 reduced equity.
- New share issuances of 554,925 increased equity.
- Other comprehensive income decreased equity by 47,821.
- Other factors increased equity by 1,240,892.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.92 Million | -164.98% |
| Share Issuances | $554.92K | +18.61% |
| Other Comprehensive Income | $-47.82K | -1.6% |
| Other Changes | $1.24 Million | +41.61% |
| Total Change | $- | -1671.84% |
Book Value vs Market Value Analysis
This analysis compares VentriPoint Diagnostics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $0.80 | $0.11 | x |
| 2006-12-31 | $1.13 | $0.11 | x |
| 2007-12-31 | $1.31 | $0.11 | x |
| 2008-12-31 | $-0.52 | $0.11 | x |
| 2009-12-31 | $-0.89 | $0.11 | x |
| 2010-12-31 | $-0.16 | $0.11 | x |
| 2011-12-31 | $-0.26 | $0.11 | x |
| 2012-12-31 | $-0.21 | $0.11 | x |
| 2013-12-31 | $-0.22 | $0.11 | x |
| 2014-12-31 | $-0.14 | $0.11 | x |
| 2015-12-31 | $-0.01 | $0.11 | x |
| 2016-12-31 | $-0.08 | $0.11 | x |
| 2017-12-31 | $-0.03 | $0.11 | x |
| 2018-12-31 | $-0.02 | $0.11 | x |
| 2019-12-31 | $-0.04 | $0.11 | x |
| 2020-12-31 | $-0.03 | $0.11 | x |
| 2021-12-31 | $0.06 | $0.11 | x |
| 2022-12-31 | $0.03 | $0.11 | x |
| 2023-12-31 | $0.00 | $0.11 | x |
| 2024-12-31 | $-0.02 | $0.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VentriPoint Diagnostics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5169.14%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-139.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -14.90% | 0.00% | 0.00x | 1.01x | $-173.17K |
| 2006 | -3.91% | 0.00% | 0.00x | 1.01x | $-93.28K |
| 2007 | -55.22% | 0.00% | 0.00x | 1.24x | $-1.63 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.03 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.52 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.46 Million |
| 2011 | 0.00% | -2213.07% | 0.06x | 0.00x | $-3.12 Million |
| 2012 | 0.00% | -1080.86% | 0.32x | 0.00x | $-3.76 Million |
| 2013 | 0.00% | -2322.38% | 0.09x | 0.00x | $-1.34 Million |
| 2014 | 0.00% | -1704.68% | 0.26x | 0.00x | $-1.95 Million |
| 2015 | 0.00% | -2714.77% | 0.03x | 0.00x | $-1.49 Million |
| 2016 | 0.00% | -1252.51% | 0.31x | 0.00x | $-2.40 Million |
| 2017 | 0.00% | -9518.58% | 0.02x | 0.00x | $-3.54 Million |
| 2018 | 0.00% | -3463.14% | 0.13x | 0.00x | $-1.99 Million |
| 2019 | 0.00% | -4100.85% | 0.26x | 0.00x | $-3.08 Million |
| 2020 | 0.00% | -5138.34% | 0.04x | 0.00x | $-1.62 Million |
| 2021 | -46.57% | 0.00% | 0.00x | 1.15x | $-4.71 Million |
| 2022 | -107.01% | -7148.33% | 0.01x | 1.31x | $-5.33 Million |
| 2023 | -2568.15% | -9905.73% | 0.03x | 9.93x | $-4.89 Million |
| 2024 | 0.00% | -5169.14% | 0.14x | 0.00x | $-4.62 Million |
Industry Comparison
This section compares VentriPoint Diagnostics Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VentriPoint Diagnostics Ltd (VPTDF) | $-4.66 Million | -14.90% | N/A | $14.70 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |